key: cord-0775113-zs556h4z
authors: Marta, G.D.H.; Auclin, E.; Saoudi Gonzalez, N.; Casadevall Aguilar, D.; Rodriguez Castells, M.; Epaillard, N.; Tagliamento, M.; Pilotto, S.; López-Castro, R.; Mielgo Rubio, X.; Urbano Centella, C.; Pineda, E.; Laia, F. M.; Mirallas, O.; Bluthgen, M. V.; Masfarré, L.; Minatta, J. N.; Cruz, C. A.; Prat, A.; Mezquita, L.
title: Active smoking and severity of COVID-19 infection in cancer patients
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.1777
sha: c5f2996a1db14164f751ce3f7ddbac03907a963c
doc_id: 775113
cord_uid: zs556h4z

nan

Background: No specific safety data concerning systemic oncological treatments were available at time of COVID-19 outbreak in Belgium. In our hospital we decided to maintain adjuvant and early line treatments for metastatic disease in patients under 65 and without specific comorbidities and to apply a shared decision approach in other patients while following closely the safety of these treatments.

Methods: Real time safety monitoring was proposed to all patients treated for solid tumours in our day-care unit starting March 1 st , 2020. After signing informed consent patients were asked questions concerning protective measures at home, signs of SARS-CoV-2 infection and hospitalisation. Patients' charts were reviewed for outcome, including death, after suspected or proven SARS-CoV-2 infection. Minimum follow-up was 5 weeks after day care unit attendance.

Results: 387 patients were included in our registry between March 1 st and March 31 st , 2020. Median age was 64 years-old (range 27-90). Most patients suffered from lung (n¼96), breast (n¼93), gastrointestinal (n¼87), gynaecological (n¼38) or urological (n¼33) cancers. 131 patients received (neo)adjuvant treatments, 256 patients were treated for metastatic disease. Patients received chemotherapy (n¼170), immunotherapy (n¼103), targeted therapy (n¼68) or other combinations (n¼46). Although Belgium had one of the highest infection rates in the world, safety data concerning risk of SARS-CoV-2 infection and outcomes were rather reassuring. A total of 11 patients had either suspected (n¼5, 1.3%) or proven (n¼6, 1.6%) SARS-CoV-2 infection. Only one 74 years old patient died of COVID-19, another 51 years old patient died of progressive disease but presented also suspicion of SARS-CoV-2 infection at the time of death.

Conclusions: Analysis of our data for patients treated in March 2020 in the day-care unit are reassuring and suggest higher risk related to under-treatment compared to risk related to continuation of systemic therapy at time of COVID-19 outbreak. Patients' follow-up will be updated and additional analyses and data in particular for April 2020, when the infection rate was still extremely high in Belgium, will be presented.

Legal entity responsible for the study: The authors. Background: Smoking is the leading cause of cancer worldwide. Active smoking alters the inflammatory environment of the respiratory epithelium, increasing the production of potent pro-inflammatory cytokines that promote the recruitment of macrophages and neutrophils, leading to lung damage. We hypothesize that smokinginduced inflammation can impact on COVID-19 infection severity and mortality related to the proinflammatory cascade.

Methods: Multicenter retrospective cohort of cancer patients (pts) with COVID-19 infection diagnosed by PCR/Ag detection (n¼274) and CT-scan (N¼13) in Mar-Apr/20r in 12 centers. Clinical and biological data were collected. Smoker was defined as active tobacco consumption and heavy smoker as >30 pack-year (PY). Primary endpoints were 30-day mortality rate and the rate of severe acute respiratory failure (SARF), defined by oxygen requirements >15 L/min.

A total of 287 pts were enrolled: 25 (9%) were active smokers, 127 (47%) were former and 116 (43%) never smoker. Among active smokers: 73% were heavy smokers, median age was 62y, 60% were male and median body mass index was 22. Regarding their comorbidities: 25% had hypertension, 8% cardiovascular disease, 28% chronic obstructive pulmonary disease and 24% diabetes. Thoracic tumors were the most common (52%), 72% had advanced disease and 56% were under systemic therapy. 92% of active smokers required hospitalization, 68% developed pneumonia and 58% required oxygen. Only 4% were escalated to the intensive care unit. Active smokers received treatment with hydroxychloroquine (91%), azithromycin (61%), antiviral therapy (33%) and steroids (29%). Only 4% received immunomodulatory drugs. SARF was the most common complication (25%) and no thromboembolic events were observed. A pro-inflammatory status was observed at COVID-19 diagnosis in active smokers, e.g. median of absolute neutrophil count was 6.35 (vs. 5.4), mean ferritin was 1269 (vs. 991) and D-Dimer was 2422 (vs. 1816); but with no significant differences. Overall mortality rate was 27%. Mortality rate was higher in active smokers (40% vs. 24% in non-smokers; p¼0.08).

Conclusions: Active smoking might be associated with severe COVID-19 infection and early death in cancer patients. Smoking induced-inflammation should be further explored.

entity responsible for the study: Aleix Prat. Funding: Has not received any funding

Speaker Bureau/Expert testimony: BMS. A. Prat: Honoraria (institution)

Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Amgen

Speaker Bureau/Expert testimony: Daiichi Sankyo; Nanostring

Advisory/Consultancy: Puma; Oncolytics Biotech; MSD; Honoraria (institution), Advisory/ Consultancy: Lilly; Boehringer

Breast International Group; Solti's Foundation; Actitud frente al cancer foundation. L. Mezquita: Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Bristol-Meyers Squibb

Speaker Bureau/Expert testimony: Astrazeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Research grant/Funding (self): Boehringer Intelligence

1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score

Hospital del Mar

Circulating inflammatory markers were collected at two timepoints: pre-COVID condition (-15 to -45d before COVID-19 diagnosis) and COVID-19 diagnosis. Tumor-induced proinflam-status was defined by high derived neutrophil to lymphocyte ratio (dNLR>3) at pre-COVID condition. COVID-induced proinflam-status was defined by +100% increase of dNLR between both timepoints. We built the FLARE score, combining both Tumor and Infection

T+/I-(T-only), if inflammation only due to tumor

I+ (I-only), if inflammation only due to COVID; and T-/I-(favorable), if no inflam-status. Primary endpoint was 30-day mortality

As per cancer characteristics: 68% had active disease, 52% advanced stage and 79% had a baseline PS1. Thoracic cancers were the most common (26%) and 61% of pts were under systemic therapy. The dNLR was high in 24% at pre-COVID condition vs. 55% at COVID-19 diagnosis

Overall mortality rate was 27%. According to FLARE score: 67% mortality for poor vs. 35% for I-only vs. 33% for T-only vs. 19% in favorable group (p¼0.008). The FLARE poor group was independently associated with 30-day mortality

Conclusions: Both tumor and infection-induced proinflam-status impact on COVID-19 outcomes in cancer pts. The FLARE score, based on simple dynamics between two timepoints, allows to identify the population at higher risk for early death. Legal entity responsible for the study: Aleix Prat. Funding: Has not received any funding

Prat: Honoraria (institution), Speaker Bureau/Expert testimony: Roche

Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Novartis; Amgen

Speaker Bureau/Expert testimony: Daiichi Sankyo; Nanostring technologies

Advisory/Consultancy: Lilly; Honoraria (institution): Boehringer

Research; Celgene; Astellas Pharma; Officer/Board of Directors: Breast International Group

Solti's Foundation; Leadership role: Actitud Frente al Cancer Foundation. L. Mezquita: Speaker Bureau/Expert testimony, Research grant/ Funding (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb

Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche

Research grant/Funding (self): Boehringer Ingelheim. All other authors have declared no conflicts of interest

Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic

Due to COVID-19, the NCCN Myeloid Growth Factor Panel expanded prophylactic G-CSF use to chemotherapy with Intermediate Risk

Preservation of resources for COVID-19 pts by reducing hospitalizations and emergency room visits by cancer chemotherapy pts is the intent of these changed recommendations. Other recommendations include use of self-injecting or on-body injector Peg, to minimize COVID-19 exposure at outpatient center by cancer pts and limiting prophylactic platelet transfusion to preserve blood product supply. Plin is an attractive alternative: it is a novel, non-G-CSF small molecule with CIN protection comparable to Peg, is given once 30 minutes after Chemo, and avoids the need for healthcare system touches on Day 1-3 for G-CSF administration. In contrast to Peg, Plin does not cause bone pain and thrombocytopenia and maintains quality of life

Plin was given as a single IV infusion on Day (D)1, 30 min after the last Chemo, and Peg 6mg given on D2 by SC injection

Conclusions: Plin requires at least 50% fewer touches to the health care system and is equally effective as Peg for prevention of CIN and its clinical sequelae. Plin causes less thrombopenia and bone pain

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2

Background: SARS-CoV-2 genome reveals a unique furin cleavage site change at S1/S2 junction and furin-like S2' cleavage site which promotes membrane fusogenic pathway entry and exit to human host cells. Clinical testing of VP, used in an autologous tumor vaccine (Vigil), demonstrates >90% knockdown of TGFb, a downstream furin protease product, elevation of GMCSF and safety and benefit in solid tumor cancer patients.